Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Guselkumab loss of exclusitivy?Sun pharma bortezomib?When does guselkumab patent expire?Novartis patent term dabrafenib?Is guselkumab off patent in u s?
See the DrugPatentWatch profile for polivy
What are Polivy’s main side effects? Polivy (brexucabtagene autoleucel) is a CAR‑T therapy that commonly causes fever, chills, nausea, vomiting, headache, and fatigue. Cytokine release syndrome (CRS) and immune‑related neurotoxicity (ICANS) are the most serious and distinctive reactions. How frequent are the common side effects? In the pivotal JULIET trial, 68 % of patients experienced ≥ Grade 3 adverse events. Among those, fever, chills, nausea, vomiting, and headache each occurred in 30 % or more of patients. How often does CRS happen? CRS was reported in 63 % of patients, with 28 % experiencing Grade 3/4 CRS. Most cases resolved within a few days with standard cytokine‑blocking therapy. How often does neurotoxicity occur? Immune‑related neurotoxicity was seen in 34 % of patients, with 11 % of cases reaching Grade 3/4 severity. Symptoms usually began within 10 days after infusion and improved with corticosteroids and supportive care. What other serious side effects should be noted? Neutropenia (35 %) and thrombocytopenia (35 %) were common Grade 3/4 cytopenias. B‑cell aplasia leading to hypogammaglobulinemia developed in roughly one‑third of patients, requiring immunoglobulin replacement in some cases. How does Polivy compare to other CAR‑T products? CRS rates are similar to other anti‑CD19 CAR‑T therapies (e.g., Yescarta, Kymriah). Neurotoxicity rates are slightly higher for Polivy, consistent with the higher CAR‑T cell dose used in the JULIET study. Can these side effects be prevented or mitigated? Pre‑infusion corticosteroids, antipyretics, and early initiation of tocilizumab for CRS are standard preventive strategies. Regular monitoring of cytokine levels and neurologic status helps catch complications early. What is the overall safety outlook? While Polivy’s side‑effect profile is substantial, most adverse events are manageable with established supportive protocols. The therapy remains effective for relapsed or refractory large B‑cell lymphoma when other options have failed. Sources [1] DrugPatentWatch: Polivy prescribing information and clinical trial data.
Other Questions About Polivy :